TiGenix kicks off Sepcell trial to test new pneumonia treatment

TiGenix has enrolled the first patient and treated in a Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).

TiGenix’s Chief Medical Officer, Marie Paule Richard said that Cx611, represents a novel approach to address severe sepsis. She explained that the SEPCELL trial will provide information on the safety, tolerability and efficacy of Cx611 as a candidate for the treatment of patients with severe sepsis.

TiGenix added in its press release on Tuesday that the SEPCELL project is also represented by a group of five European research institutes that bring together the necessary competencies, expertise and resources to achieve the project’s goals. SEPCELL has been awarded a EUR 5.4 million grant by the European Union under the Horizon 2020 Research and Innovation Programme under Grant Agreement 681031.